Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials

Pharmacology and Therapeutics

Volumn 158, Issue , 2016, Pages 24-40

  Van Acker, Heleen H ^a   Anguille, Sébastien ^a,b   Willemen, Yannick ^a   Smits, Evelien L ^a,b   Van Tendeloo, Viggo F ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bisphosphonates; Cancer immunology; Clinical trials; Direct anti cancer effects; Hematological malignancies; Solid tumors

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETIDRONIC ACID; GOSERELIN; IBANDRONIC ACID; IMATINIB; INTERLEUKIN 2; LETROZOLE; METHOTREXATE; PAMIDRONIC ACID; RISEDRONIC ACID; SIMVASTATIN; THALIDOMIDE; TILUDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BONE ATROPHY; BONE DENSITY; BONE METASTASIS; BONE TUMOR; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; CELL INVASION; CLINICAL TRIAL (TOPIC); DRUG MECHANISM; DRUG POTENTIATION; FRAGILITY FRACTURE; GAMMA DELTA T LYMPHOCYTE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSURVEILLANCE; JAW OSTEONECROSIS; KIDNEY CARCINOMA; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOLID TUMOR; SYSTEMIC THERAPY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR INVASION; ANIMAL; DRUG EFFECTS; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL ADHESION; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; HUMANS; NEOPLASMS;

EID: 84957438917     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.11.008     Document Type: Review

References (188)

1. M. Aapro, P.A. Abrahamsson, J.J. Body, R.E. Coleman, R. Colomer, L. Costa, and et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 2008 420 432
2. Y. Abe, M. Muto, M. Nieda, Y. Nakagawa, A. Nicol, T. Kaneko, and et al. Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma Exp Hematol 37 2009 956 968
3. C.L. Addison, N. Bouganim, J. Hilton, L. Vandermeer, S. Dent, E. Amir, and et al. A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events Breast Cancer Res Treat 144 2014 615 624
4. R. Aft, M. Naughton, K. Trinkaus, M. Watson, L. Ylagan, M. Chavez-MacGregor, and et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial Lancet Oncol 11 2010 421 428
5. R.L. Aft, M. Naughton, K. Trinkaus, and K. Weilbaecher Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer Br J Cancer 107 2012 7 11
6. D. Amadori, M. Aglietta, B. Alessi, L. Gianni, T. Ibrahim, G. Farina, and et al. Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial Lancet Oncol 14 2013 663 670
7. S. Atula, T. Powles, A. Paterson, E. McCloskey, J. Nevalainen, and J. Kanis Extended safety profile of oral clodronate after long-term use in primary breast cancer patients Drug Saf 26 2003 661 671
8. A. Aviles, M.J. Nambo, N. Neri, C. Castaneda, S. Cleto, and J. Huerta-Guzman Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma Med Oncol 24 2007 227 230
9. A. Aviles, N. Neri, J. Huerta-Guzman, and M.J. Nambo Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation Curr Oncol 20 2013 e13 e20
10. M. Balke, L. Campanacci, C. Gebert, P. Picci, M. Gibbons, R. Taylor, and et al. Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone BMC Cancer 10 2010 462
11. M. Banys, E.F. Solomayer, G. Gebauer, W. Janni, N. Krawczyk, H.J. Lueck, and et al. Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial BMC Cancer 13 2013 480
12. P. Barrett-Lee, A. Casbard, J. Abraham, K. Hood, R. Coleman, P. Simmonds, and et al. Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial Lancet Oncol 15 2014 114 122
13. J.J. Body, I.J. Diel, M.R. Lichinitser, E.D. Kreuser, W. Dornoff, V.A. Gorbunova, and et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases Ann Oncol 14 2003 1399 1405
14. J.J. Body, I.J. Diel, M. Lichinitzer, A. Lazarev, M. Pecherstorfer, R. Bell, and et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies Br J Cancer 90 2004 1133 1137
15. A.K. Bonde, V. Tischler, S. Kumar, A. Soltermann, and R.A. Schwendener Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors BMC Cancer 12 2012 35
16. M.S. Braza, and B. Klein Anti-tumour immunotherapy with Vgamma9Vdelta2 T lymphocytes: from the bench to the bedside Br J Haematol 160 2013 123 132
17. A. Charehbili, S. van de Ven, V.T. Smit, E. Meershoek-Klein Kranenbarg, N.A. Hamdy, H. Putter, and et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01) Ann Oncol 25 2014 998 1004
18. H. Ciepluch, W. Baran, and A. Hellmann Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma Med Sci Monit 8 2002 I31 I36
19. P. Clezardin Potential anticancer properties of bisphosphonates: insights from preclinical studies Anti Cancer Agents Med Chem 12 2012 102 113
20. R.E. Coleman Risks and benefits of bisphosphonates Br J Cancer 98 2008 1736 1740
21. R. Coleman, D. Cameron, D. Dodwell, R. Bell, C. Wilson, E. Rathbone, and et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial Lancet Oncol 15 2014 997 1006
22. R. Coleman, M. Gnant, G. Morgan, and P. Clezardin Effects of bone-targeted agents on cancer progression and mortality J Natl Cancer Inst 104 2012 1059 1067
23. R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, and et al. Breast-cancer adjuvant therapy with zoledronic acid N Engl J Med 365 2011 1396 1405
24. R.E. Coleman, M.C. Winter, D. Cameron, R. Bell, D. Dodwell, M.M. Keane, and et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 2010 1099 1105
25. F. Cornelis, M.E. Truchetet, N. Amoretti, D. Verdier, C. Fournier, O. Pillet, and et al. Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy Bone 58 2014 11 16
26. A. Corso, E. Ferretti, M. Lunghi, P. Zappasodi, S. Mangiacavalli, M. De Amici, and et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect Cancer 104 2005 118 125
27. M. Coscia, E. Quaglino, M. Iezzi, C. Curcio, F. Pantaleoni, C. Riganti, and et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway J Cell Mol Med 14 2010 2803 2815
28. L. Costa, A. Lipton, P. Hadji, Y.M. Chen, and P. Kosmidis Treatment of bone metastases before the onset of pain Int J Clin Oncol 18 2013 531 538
29. J.P. Coxon, G.M. Oades, R.S. Kirby, and K.W. Colston Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation BJU Int 94 2004 164 170
30. F.P. Coxon, K. Thompson, and M.J. Rogers Recent advances in understanding the mechanism of action of bisphosphonates Curr Opin Pharmacol 6 2006 307 312
31. G. D'Arena, P.G. Gobbi, C. Broglia, S. Sacchi, G. Quarta, L. Baldini, and et al. Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study Leuk Lymphoma 52 2011 771 775
32. G. De Rosa, G. Misso, G. Salzano, and M. Caraglia Bisphosphonates and cancer: what opportunities from nanotechnology? J Drug Deliv 2013 2013 637976
33. D.P. Dearnaley, M.D. Mason, M.K. Parmar, K. Sanders, and M.R. Sydes Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials Lancet Oncol 10 2009 872 876
34. P.G. Dedes, C. Gialeli, A.I. Tsonis, I. Kanakis, A.D. Theocharis, D. Kletsas, and et al. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid Biochim Biophys Acta 1820 2012 1926 1939
35. X. Deng, G. He, J. Liu, F. Luo, X. Peng, S. Tang, and et al. Recent advances in bone-targeted therapies of metastatic prostate cancer Cancer Treat Rev 40 2014 730 738
36. J.W. Denham, D. Joseph, D.S. Lamb, N.A. Spry, G. Duchesne, J. Matthews, and et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial Lancet Oncol 15 2014 1076 1089
37. J.W. Denham, C. Wilcox, D. Joseph, N.A. Spry, D.S. Lamb, K.H. Tai, and et al. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial Lancet Oncol 13 2012 1260 1270
38. J.W. Denham, C. Wilcox, D.S. Lamb, N.A. Spry, G. Duchesne, C. Atkinson, and et al. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer Radiother Oncol 105 2012 184 192
39. I.J. Diel, A. Jaschke, E.F. Solomayer, C. Gollan, G. Bastert, C. Sohn, and et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up Ann Oncol 19 2008 2007 2011
40. F. Dieli, D. Vermijlen, F. Fulfaro, N. Caccamo, S. Meraviglia, G. Cicero, and et al. Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer Cancer Res 67 2007 7450 7457
41. M.T. Drake, B.L. Clarke, and S. Khosla Bisphosphonates: mechanism of action and role in clinical practice Mayo Clin Proc 83 2008 1032 1045
42. Early Breast Cancer Trialists' Collaborative Group Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials Lancet 386 10001 2015 1353 1361
43. Q.M. Fan, Y.Y. Jing, G.F. Yu, X.R. Kou, F. Ye, L. Gao, and et al. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma Cancer Lett 352 2014 160 168
44. P.A. Fasching, S.M. Jud, M. Hauschild, S. Kummel, M. Schutte, M. Warm, and et al. FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients BMC Cancer 14 2014 66
45. O. Filleul, E. Crompot, and S. Saussez Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases J Cancer Res Clin Oncol 136 2010 1117 1124
46. C. Foroni, M. Milan, C. Strina, M. Cappelletti, C. Fumarola, M. Bonelli, and et al. Pure anti-tumor effect of zoledronic acid in naive bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy" Breast Cancer Res Treat 144 2014 113 121
47. F. Francini, A. Pascucci, G. Bargagli, E. Francini, R. Conca, S.T. Miano, and et al. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer Int J Clin Oncol 16 2011 264 269
48. T. Fujiwara, J. Fukushi, S. Yamamoto, Y. Matsumoto, N. Setsu, Y. Oda, and et al. Macrophage infiltration predicts a poor prognosis for human ewing sarcoma Am J Pathol 179 2011 1157 1170
49. S. Ganguly, C.L. Divine, O.S. Aljitawi, S. Abhyankar, J.P. McGuirk, and L. Graves Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation Clin Transpl 26 2012 447 453
50. P. Gimsing, K. Carlson, I. Turesson, P. Fayers, A. Waage, A. Vangsted, and et al. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial Lancet Oncol 11 2010 973 982
51. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 2004 623 633
52. M. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth, F. Kainberger, H. Kassmann, J.C. Piswanger-Solkner, and et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 2008 840 849
53. M. Gnant, B. Mlineritsch, W. Schippinger, G. Luschin-Ebengreuth, S. Postlberger, C. Menzel, and et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
54. M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, D. Heck, C. Menzel, and et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial Lancet Oncol 12 2011 631 641
55. M. Gnant, B. Mlineritsch, H. Stoeger, G. Luschin-Ebengreuth, M. Knauer, M. Moik, and et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 Ann Oncol 26 2015 313 320
56. H.J. Gober, M. Kistowska, L. Angman, P. Jeno, L. Mori, and G. De Libero Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells J Exp Med 197 2003 163 168
57. R.E. Goldsby, T.M. Fan, D. Villaluna, L.M. Wagner, M.S. Isakoff, J. Meyer, and et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Eur J Cancer 49 2013 2384 2391
58. V. Gonzalez-Villasana, E. Fuentes-Mattei, C. Ivan, H.J. Dalton, C. Rodriguez-Aguayo, R.J. Fernandez-de Thomas, and et al. Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer Clin Cancer Res 21 2015 2127 2137
59. J. Green, and A. Lipton Anticancer properties of zoledronic acid Cancer Invest 28 2010 944 957
60. S. Gu, W. Nawrocka, and E.J. Adams Sensing of pyrophosphate metabolites by Vgamma9Vdelta2 T cells Front Immunol 5 2014 688
61. A. Guenther, S. Gordon, M. Tiemann, R. Burger, F. Bakker, J.R. Green, and et al. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation Int J Cancer 126 2010 239 246
62. N.B. Hao, M.H. Lu, Y.H. Fan, Y.L. Cao, Z.R. Zhang, and S.M. Yang Macrophages in tumor microenvironments and the progression of tumors Clin Dev Immunol 2012 2012 948098
63. K. Harnden, and K. Blackwell Routine use of zoledronic acid in early-stage breast cancer J Natl Compr Canc Netw 13 2015 480 486
64. K. Hashimoto, N. Masumori, T. Tanaka, T. Maeda, K. Kobayashi, H. Kitamura, and et al. Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer Prostate 73 2013 500 511
65. A. Heidenreich, P.J. Bastian, J. Bellmunt, M. Bolla, S. Joniau, T. van der Kwast, and et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
66. P. Heras, S. Karagiannis, K. Kritikos, A. Hatzopoulos, and D. Mitsibounas Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer Eur J Cancer Care (Engl) 16 2007 539 542
67. P. Heras, K. Kritikos, A. Hatzopoulos, and A.P. Georgopoulou Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer Eur J Cancer Care (Engl) 18 2009 653 656
68. R.E. Hewitt, A. Lissina, A.E. Green, E.S. Slay, D.A. Price, and A.K. Sewell The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins Clin Exp Immunol 139 2005 101 111
69. O. Hoffmann, B. Aktas, C. Goldnau, M. Heubner, C. Oberhoff, R. Kimmig, and et al. Effect of ibandronate on disseminated tumor cells in the bone marrow of patients with primary breast cancer: a pilot study Anticancer Res 31 2011 3623 3628
70. T.F. Hue, S.R. Cummings, J.A. Cauley, D.C. Bauer, K.E. Ensrud, E. Barrett-Connor, and et al. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid JAMA Intern Med 174 2014 1550 1557
71. L. Insalaco, F. Di Gaudio, M. Terrasi, V. Amodeo, S. Caruso, L.R. Corsini, and et al. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells J Cell Mol Med 16 2012 2186 2195
72. P. Italiani, and D. Boraschi From monocytes to M1/M2 macrophages: phenotypical vs functional differentiation Front Immunol 5 2014 514
73. N.D. James, M.R. Spears, N.W. Clarke, D.P. Dearnaley, J.S. De Bono, J. Gale, and et al. Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era": data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) Eur Urol 67 2015 1028 1038
74. S. Junankar, G. Shay, J. Jurczyluk, N. Ali, J. Down, N. Pocock, and et al. Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer Cancer Discov 5 2015 35 42
75. N. Kamiya, H. Suzuki, T. Endo, M. Takano, M. Yano, M. Naoi, and et al. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade Int J Urol 19 2012 169 173
76. H. Kawashima, T. Tanaka, K. Kuratsukuri, J. Uchida, K. Sugimura, S. Tamada, and et al. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels Urol Int 78 2007 345 350
77. D.B. Kimmel Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates J Dent Res 86 2007 1022 1033
78. H. Knupfer, and R. Preiss sIL-6R: more than an agonist? Immunol Cell Biol 86 2008 87 91
79. R.S. Kotecha, N. Powers, S.J. Lee, K.J. Murray, T. Carter, and C. Cole Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL) Pediatr Blood Cancer 54 2010 934 940
80. V. Kouloulias, G. Matsopoulos, J. Kouvaris, C. Dardoufas, A. Bottomley, M. Varela, and et al. Radiotherapy in conjunction with intravenous infusion of 180 mg of disodium pamidronate in management of osteolytic metastases from breast cancer: clinical evaluation, biochemical markers, quality of life, and monitoring of recalcification using assessments of gray-level histogram in plain radiographs Int J Radiat Oncol Biol Phys 57 2003 143 157
81. V. Kreutle, C. Blum, C. Meier, M. Past, B. Muller, P. Schutz, and et al. Bisphosphonate induced hypocalcaemia - report of six cases and review of the literature Swiss Med Wkly 144 2014 w13979
82. B. Kristensen, B. Ejlertsen, H.T. Mouridsen, M.B. Jensen, J. Andersen, B. Bjerregaard, and et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer Acta Oncol 47 2008 740 746
83. V. Kunzmann, M. Smetak, B. Kimmel, K. Weigang-Koehler, M. Goebeler, J. Birkmann, and et al. Tumor-promoting versus tumor-antagonizing roles of gammadelta T cells in cancer immunotherapy: results from a prospective phase I/II trial J Immunother 35 2012 205 213
84. J.M. Lang, M.R. Kaikobad, M. Wallace, M.J. Staab, D.L. Horvath, G. Wilding, and et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma Cancer Immunol Immunother 60 2011 1447 1460
85. A. Larocca, J.A. Child, G. Cook, G.H. Jackson, N. Russell, A. Szubert, and et al. The impact of response on bone-directed therapy in patients with multiple myeloma Blood 122 2013 2974 2977
86. C. Leblicq, C. Laverdiere, J.C. Decarie, J.F. Delisle, M.H. Isler, A. Moghrabi, and et al. Effectiveness of pamidronate as treatment of symptomatic osteonecrosis occurring in children treated for acute lymphoblastic leukemia Pediatr Blood Cancer 60 2013 741 747
87. S.H. Lee, R.C. Chan, S.S. Chang, Y.L. Tan, K.H. Chang, M.C. Lee, and et al. Use of bisphosphonates and the risk of osteonecrosis among cancer patients: a systemic review and meta-analysis of the observational studies Support Care Cancer 22 2014 553 560
88. J.H. Lee, G.T. Lee, S.H. Woo, Y.S. Ha, S.J. Kwon, W.J. Kim, and et al. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages Cancer Res 73 2013 3604 3614
89. S. Leppa, T. Saarto, L. Vehmanen, C. Blomqvist, and I. Elomaa Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer Breast Cancer Res Treat 90 2005 117 125
90. A. Lipton, R.L. Theriault, G.N. Hortobagyi, J. Simeone, R.D. Knight, K. Mellars, and et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials Cancer 88 2000 1082 1090
91. H. Lu, K.R. Clauser, W.L. Tam, J. Frose, X. Ye, E.N. Eaton, and et al. A breast cancer stem cell niche supported by juxtacrine signalling from monocytes and macrophages Nat Cell Biol 16 2014 1105 1117
92. S. Mariani, M. Muraro, F. Pantaleoni, F. Fiore, B. Nuschak, S. Peola, and et al. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma Leukemia 19 2005 664 670
93. E.V. McCloskey, J.A. Dunn, J.A. Kanis, I.C. MacLennan, and M.T. Drayson Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma Br J Haematol 113 2001 1035 1043
94. E. McCloskey, A. Paterson, J. Kanis, R. Tahtela, and T. Powles Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer Eur J Cancer 46 2010 558 565
95. Y. Meng, M.A. Beckett, H. Liang, H.J. Mauceri, N. van Rooijen, K.S. Cohen, and et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy Cancer Res 70 2010 1534 1543
96. H.D. Menssen, A. Sakalova, A. Fontana, Z. Herrmann, C. Boewer, T. Facon, and et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma J Clin Oncol 20 2002 2353 2359
97. S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri, G. Cicero, and et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients Clin Exp Immunol 161 2010 290 297
98. H.J. Meulenbeld, E.D. van Werkhoven, J.L. Coenen, G.J. Creemers, O.J. Loosveld, P.C. de Jong, and et al. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro) Eur J Cancer 48 2012 2993 3000
99. P.A. Meyers, J.H. Healey, A.J. Chou, L.H. Wexler, P.R. Merola, C.D. Morris, and et al. Addition of pamidronate to chemotherapy for the treatment of osteosarcoma Cancer 117 2011 1736 1744
100. R. Mhaskar, J. Redzepovic, K. Wheatley, O.A. Clark, B. Miladinovic, A. Glasmacher, and et al. Bisphosphonates in multiple myeloma: a network meta-analysis Cochrane Database Syst Rev 5 2012 CD003188
101. P.D. Miller The kidney and bisphosphonates Bone 49 2011 77 81
102. P.D. Miller, S.A. Jamal, P. Evenepoel, R. Eastell, and S. Boonen Renal safety in patients treated with bisphosphonates for osteoporosis: a review J Bone Miner Res 28 2013 2049 2059
103. L.M. Mitrofan, J. Pelkonen, and J. Monkkonen The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro Bone 45 2009 1153 1160
104. M.F. Moreau, C. Guillet, P. Massin, S. Chevalier, H. Gascan, M.F. Basle, and et al. Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro Biochem Pharmacol 73 2007 718 723
105. G.J. Morgan, F.E. Davies, W.M. Gregory, S.E. Bell, A.J. Szubert, G. Cook, and et al. Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment Clin Cancer Res 19 2013 6030 6038
106. G.J. Morgan, F.E. Davies, W.M. Gregory, K. Cocks, S.E. Bell, A.J. Szubert, and et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial Lancet 376 2010 1989 1999
107. G.J. Morgan, F.E. Davies, W.M. Gregory, A.J. Szubert, S.E. Bell, M.T. Drayson, and et al. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial Blood 119 2012 5374 5383
108. M. Moschetta, G. Di Pietro, R. Ria, A. Gnoni, G. Mangialardi, A. Guarini, and et al. Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma Eur J Cancer 46 2010 420 429
109. H. Murakami, T. Yamanaka, T. Seto, K. Sugio, I. Okamoto, T. Sawa, and et al. Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group Cancer Sci 105 2014 989 995
110. P. Musto, A. Falcone, G. Sanpaolo, C. Bodenizza, N. Cascavilla, L. Melillo, and et al. Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial Leuk Lymphoma 44 2003 1545 1548
111. P. Musto, M.T. Petrucci, S. Bringhen, T. Guglielmelli, T. Caravita, V. Bongarzoni, and et al. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma Cancer 113 2008 1588 1595
112. National Comprehensive Cancer Network (NCCN), 2015. Breast Cancer (Version 3.2015). In (Vol. 2015); 2015.
113. G.A. Odri, S. Dumoucel, G. Picarda, S. Battaglia, F. Lamoureux, N. Corradini, and et al. Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients Cancer Res 70 2010 7610 7619
114. G. Odri, P.P. Kim, F. Lamoureux, C. Charrier, S. Battaglia, J. Amiaud, and et al. Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration BMC Cancer 14 2014 169
115. T. Ohba, J.M. Cates, H.A. Cole, D.A. Slosky, H. Haro, J. Ichikawa, and et al. Pleiotropic effects of bisphosphonates on osteosarcoma Bone 63 2014 110 120
116. T. Ohba, H.A. Cole, J.M. Cates, D.A. Slosky, H. Haro, T. Ando, and et al. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL J Bone Miner Res 29 2014 1431 1445
117. T. Okegawa, M. Higaki, T. Matsumoto, H. Kase, A. Murata, K. Noda, and et al. Zoledronic acid improves clinical outcomes in patients with bone metastatic hormone-naive prostate cancer in a multicenter clinical trial Anticancer Res 34 2014 4415 4420
118. J.E. Otero, J.W. Stevens, A.E. Malandra, D.C. Fredericks, P.R. Odgren, J.A. Buckwalter, and et al. Osteoclast inhibition impairs chondrosarcoma growth and bone destruction J Orthop Res 32 2014 1562 1571
119. P.D. Ottewell, N. Wang, H.K. Brown, K.J. Reeves, C.A. Fowles, P.I. Croucher, and et al. Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo Clin Cancer Res 20 2014 2922 2932
120. A.H. Paterson, S.J. Anderson, B.C. Lembersky, L. Fehrenbacher, C.I. Falkson, K.M. King, and et al. Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial Lancet Oncol 13 2012 734 742
121. J. Pavlu, C. Andreasson, C. Chuah, J. Kaeda, J.M. Goldman, J.F. Apperley, and et al. Dual inhibition of ras and bcr-abl signalling pathways in chronic myeloid leukaemia: a phase I/II study in patients in complete haematological remission Br J Haematol 137 2007 423 428
122. M. Pazianas, S.M. Kim, T. Yuen, L. Sun, S. Epstein, and M. Zaidi Questioning the association between bisphosphonates and atypical femoral fractures Ann N Y Acad Sci 1335 2015 1 9
123. T. Powles, A. Paterson, E. McCloskey, P. Schein, B. Scheffler, A. Tidy, and et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] Breast Cancer Res 8 2006 R13
124. B. Rack, J. Juckstock, E.M. Genss, A. Schoberth, C. Schindlbeck, B. Strobl, and et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer Anticancer Res 30 2010 1807 1813
125. K. Ramanlal Chaudhari, A. Kumar, V.K. Megraj Khandelwal, M. Ukawala, A.S. Manjappa, A.K. Mishra, and et al. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel J Control Release 158 2012 470 478
126. M.M. Reinholz, S.P. Zinnen, A.C. Dueck, D. Dingli, G.G. Reinholz, L.A. Jonart, and et al. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites Bone 47 2010 12 22
127. T.L. Rogers, and I. Holen Tumour macrophages as potential targets of bisphosphonates J Transl Med 9 2011 177
128. L.S. Rosen, D.H. Gordon, W. Dugan Jr., P. Major, P.D. Eisenberg, L. Provencher, and et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion Cancer 100 2004 36 43
129. L.S. Rosen, D. Gordon, M. Kaminski, A. Howell, A. Belch, J. Mackey, and et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial Cancer 98 2003 1735 1744
130. H.V. Russell, S.G. Groshen, T. Ara, Y.A. DeClerck, R. Hawkins, H.A. Jackson, and et al. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study Pediatr Blood Cancer 57 2011 275 282
131. F. Saad, J.E. Brown, C. Van Poznak, T. Ibrahim, S.M. Stemmer, A.T. Stopeck, and et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases Ann Oncol 23 2012 1341 1347
132. F. Saad, Y.M. Chen, D.M. Gleason, and J. Chin Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases Clin Genitourin Cancer 5 2007 390 396
133. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, L. Lacombe, and et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 2004 879 882
134. F. Saad, S. Segal, and J. Eastham Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid Eur Urol 65 2014 146 153
135. T. Saarto, L. Vehmanen, P. Virkkunen, and C. Blomqvist Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients Acta Oncol 43 2004 650 656
136. R. Sabatino, A. Antonelli, S. Battistelli, R. Schwendener, M. Magnani, and L. Rossi Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells PLoS One 9 2014 e101260
137. A. Saitoh, M. Narita, N. Watanabe, N. Tochiki, N. Satoh, J. Takizawa, and et al. Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma Med Oncol 25 2008 137 147
138. K.M. Sanfilippo, B. Gage, S. Luo, K. Weilbaecher, M. Tomasson, R. Vij, and et al. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma Leuk Lymphoma 56 2015 615 621
139. D. Santini, M. Caraglia, B. Vincenzi, I. Holen, S. Scarpa, A. Budillon, and et al. Mechanisms of disease: preclinical reports of antineoplastic synergistic action of bisphosphonates Nat Clin Pract Oncol 3 2006 325 338
140. D. Santini, F. Martini, M.E. Fratto, S. Galluzzo, B. Vincenzi, C. Agrati, and et al. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients Cancer Immunol Immunother 58 2009 31 38
141. D. Santini, B. Vincenzi, G. Dicuonzo, G. Avvisati, C. Massacesi, F. Battistoni, and et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients Clin Cancer Res 9 2003 2893 2897
142. G.V. Scagliotti, P. Kosmidis, F. de Marinis, A.J. Schreurs, I. Albert, W. Engel-Riedel, and et al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study Ann Oncol 23 2012 2082 2087
143. C. Scavelli, G. Di Pietro, T. Cirulli, M. Coluccia, A. Boccarelli, T. Giannini, and et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma Mol Cancer Ther 6 2007 3256 3262
144. J. Schilcher, K. Michaelsson, and P. Aspenberg Bisphosphonate use and atypical fractures of the femoral shaft N Engl J Med 364 2011 1728 1737
145. C. Schiraldi, S. Zappavigna, A. D. A., S. Porto, O. Gaito, S. Lusa, and et al. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique Cancer Biol Ther 15 2014 1524 1532
146. E. Shane Evolving data about subtrochanteric fractures and bisphosphonates N Engl J Med 362 2010 1825 1827
147. N. Silvestris, F. Pantano, T. Ibrahim, T. Gamucci, F. De Vita, T. Di Palma, and et al. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey PLoS One 8 2013 e74402
148. E.S. Siris, W.H. Sherman, D.C. Baquiran, J.P. Schlatterer, E.F. Osserman, and R.E. Canfield Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma N Engl J Med 302 1980 310 315
149. M.R. Smith, S. Halabi, C.J. Ryan, A. Hussain, N. Vogelzang, W. Stadler, and et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance) J Clin Oncol 32 2014 1143 1150
150. E.F. Solomayer, G. Gebauer, P. Hirnle, W. Janni, H.J. Luck, S. Becker, and et al. Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients Ann Oncol 23 2012 2271 2277
151. A. Stachnik, T. Yuen, J. Iqbal, M. Sgobba, Y. Gupta, P. Lu, and et al. Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer Proc Natl Acad Sci U S A 111 2014 17995 18000
152. A. Streitbuerger, M. Henrichs, H. Ahrens, C. Lanvers-Kaminzky, F. Gouin, G. Gosheger, and et al. Cytotoxic effect of clodronate and zoledronate on the chondrosarcoma cell lines HTB-94 and CAL-78 Int Orthop 35 2011 1369 1373
153. V. Stresing, P.G. Fournier, A. Bellahcene, I. Benzaid, H. Monkkonen, M. Colombel, and et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase Bone 48 2011 259 266
154. E. Sumi, T. Sugie, K. Yoshimura, H. Tada, T. Ikeda, E. Suzuki, and et al. Effects of zoledronic acid and the association between its efficacy and gammadeltaT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol J Transl Med 12 2014 310
155. D.L. Suzman, S.A. Boikos, and M.A. Carducci Bone-targeting agents in prostate cancer Cancer Metastasis Rev 33 2014 619 628
156. T. Tamura, K. Shomori, M. Nakabayashi, N. Fujii, K. Ryoke, and H. Ito Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines Oncol Rep 25 2011 1139 1143
157. E. Terpos, G. Morgan, M.A. Dimopoulos, M.T. Drake, S. Lentzsch, N. Raje, and et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease J Clin Oncol 31 2013 2347 2357
158. E. Terpos, J. Palermos, K. Tsionos, K. Anargyrou, N. Viniou, P. Papassavas, and et al. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma Eur J Haematol 65 2000 331 336
159. E. Terpos, N. Viniou, J. de la Fuente, J. Meletis, E. Voskaridou, C. Karkantaris, and et al. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma Eur J Haematol 70 2003 34 42
160. S.I. Thamake, S.L. Raut, Z. Gryczynski, A.P. Ranjan, and J.K. Vishwanatha Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer Biomaterials 33 2012 7164 7173
161. R. Torres Martin de Rosales, C. Finucane, J. Foster, S.J. Mather, and P.J. Blower 188Re(CO)3-dipicolylamine-alendronate: a new bisphosphonate conjugate for the radiotherapy of bone metastases Bioconjug Chem 21 2010 811 815
162. D. Tripathy, M. Lichinitzer, A. Lazarev, S.A. MacLachlan, J. Apffelstaedt, M. Budde, and et al. Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial Ann Oncol 15 2004 743 750
163. M. Tsubaki, T. Satou, T. Itoh, M. Imano, M. Ogaki, M. Yanae, and et al. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway Toxicol Appl Pharmacol 259 2012 402 410
164. R. Uchida, E. Ashihara, K. Sato, S. Kimura, J. Kuroda, M. Takeuchi, and et al. Gamma delta T cells kill myeloma cells by sensing mevalonate metabolites and ICAM-1 molecules on cell surface Biochem Biophys Res Commun 354 2007 613 618
165. H. Uemura, M. Yanagisawa, I. Ikeda, K. Fujinami, A. Iwasaki, S. Noguchi, and et al. Possible anti-tumor activity of initial treatment with zoledronic acid with hormonal therapy for bone-metastatic prostate cancer in multicenter clinical trial Int J Clin Oncol 18 2013 472 477
166. S. Ueno, A. Mizokami, T. Fukagai, N. Fujimoto, H. Oh-Oka, Y. Kondo, and et al. Efficacy of combined androgen blockade with zoledronic acid treatment in prostate cancer with bone metastasis: the ZABTON-PC (zoledronic acid/androgen blockade trial on prostate cancer) study Anticancer Res 33 2013 3837 3844
167. H.H. Van Acker, S. Anguille, V.F. Van Tendeloo, and E. Lion Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy OncoImmunology 4 2015 e1021538
168. N.W. van de Donk, M.M. Kamphuis, B. van Kessel, H.M. Lokhorst, and A.C. Bloem Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels Blood 102 2003 3354 3362
169. J.D. Veltman, M.E. Lambers, M. van Nimwegen, R.W. Hendriks, H.C. Hoogsteden, J.P. Hegmans, and et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma Br J Cancer 103 2010 629 641
170. G. von Minckwitz, V. Mobus, A. Schneeweiss, J. Huober, C. Thomssen, M. Untch, and et al. German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer J Clin Oncol 31 2013 3531 3539
171. F. Wang, W. Chen, H. Chen, L. Mo, H. Jin, Z. Yu, and et al. Comparison between zoledronic acid and clodronate in the treatment of prostate cancer patients with bone metastases Med Oncol 30 2013 657
172. N.B. Watts, and D.L. Diab Long-term use of bisphosphonates in osteoporosis J Clin Endocrinol Metab 95 2010 1555 1565
173. J.R. Westin, M.A. Thompson, V.D. Cataldo, L.E. Fayad, N. Fowler, M.A. Fanale, and et al. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial Clin Lymphoma Myeloma Leuk 13 2013 99 105
174. L. Widler, W. Jahnke, and J.R. Green The chemistry of bisphosphonates: from antiscaling agents to clinical therapeutics Anti Cancer Agents Med Chem 12 2012 95 101
175. M.C. Winter, C. Wilson, S.P. Syddall, S.S. Cross, A. Evans, C.E. Ingram, and et al. Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer - a randomized biomarker pilot study Clin Cancer Res 19 2013 2755 2765
176. M. Wirth, T. Tammela, V. Cicalese, F. Gomez Veiga, K. Delaere, K. Miller, and et al. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) Eur Urol 67 2015 482 491
177. X. Wu, B.C. Schulte, Y. Zhou, D. Haribhai, A.C. Mackinnon, J.A. Plaza, and et al. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo J Invest Dermatol 134 2014 2814 2822
178. L. Xia, W. Huang, D. Tian, L. Zhang, X. Qi, Z. Chen, and et al. Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression Hepatology 59 2014 958 973
179. Y. Xia, Y.L. Liu, Y. Xie, W. Zhu, F. Guerra, S. Shen, and et al. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin Sci Transl Med 6 2014 263ra161
180. J. Yamada, N.H. Tsuno, J. Kitayama, T. Tsuchiya, S. Yoneyama, M. Asakage, and et al. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation J Surg Res 151 2009 115 120
181. T. Yan, W. Yin, Q. Zhou, L. Zhou, Y. Jiang, Y. Du, and et al. The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials Eur J Cancer 48 2012 187 195
182. K. Yang, and L.W. Fu Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: a review Crit Rev Oncol Hematol 93 2015 277 292
183. W.L. Ye, Y.P. Zhao, H.Q. Li, R. Na, F. Li, Q.B. Mei, and et al. Doxorubicin-poly (ethylene glycol)-alendronate self-assembled micelles for targeted therapy of bone metastatic cancer Sci Rep 5 2015 14614
184. T. Yuen, A. Stachnik, J. Iqbal, M. Sgobba, Y. Gupta, P. Lu, and et al. Bisphosphonates inactivate human EGFRs to exert antitumor actions Proc Natl Acad Sci U S A 111 2014 17989 17994
185. M.S. Zaghloul, R. Boutrus, H. El-Hossieny, Y.A. Kader, I. El-Attar, and M. Nazmy A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer Int J Clin Oncol 15 2010 382 389
186. X. Zhao, X. Xu, L. Guo, J. Ragaz, H. Guo, J. Wu, and et al. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance Breast Cancer Res Treat 124 2010 733 743
187. X. Zhao, X. Xu, Q. Zhang, Z. Jia, S. Sun, J. Zhang, and et al. Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid BMC Cancer 11 2011 403
188. Y.Y. Zhao, C. Xue, X. Hou, H. Liao, S. Li, H.Y. Zhao, and et al. Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases Eur J Cancer 47 2011 848 853